ストックスクリーナーアプリを入手
1.91
2.69%
0.05
Armata Pharmaceuticals Inc (ARMP) 最新ニュース
Armata Pharmaceuticals Elects Board Members at Annual Meeting - TipRanks
Chronic Pseudomonas aeruginosa Pulmonary Infections Pipeline - openPR.com
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - Seeking Alpha
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0% - Defense World
10 Best Healthcare Stocks to Invest In (June 2025) - Securities.io
ARMP Soars 72% in a Month Following Infectious Disease Study Success - MSN
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Biotech Alert: Searches spiking for these stocks today - TipRanks
Armata Pharmaceuticals (ARMP) Experiences Massive Surge in Inter - GuruFocus
Armata Pharmaceuticals Q4 EPS Reduced by HC Wainwright - Defense World
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Price Target Raised to $9.00 at HC Wainwright - Defense World
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | ARMP Stock News - GuruFocus
Armata Pharmaceuticals (ARMP) Receives Boosted Price Target from - GuruFocus
HC Wainwright Adjusts Armata Pharmaceuticals Price Target to $9 From $7, Maintains Buy Rating - marketscreener.com
Armata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Tria - GuruFocus
Armata reports data from Phase 1b/2a diSArm trial - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus
ARMP: Positive Results from Armata Pharmaceuticals' AP-SA02 Trial | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Reports Positive Phase 1b/2a Trial Results - TipRanks
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PR Newswire
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates - MSN
Armata Pharmaceuticals Inc (ARMP) Q1 Earnings: EPS Loss of $0.18 - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update | ARMP Stock News - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - Financial Times
New Strong Sell Stocks for May 8th - The Globe and Mail
Armata Pharmaceuticals (ARMP) to Release Earnings on Tuesday - Defense World
Armata Pharmaceuticals secures additional DoD funding - Investing.com
Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 | ARMP Stock News - GuruFocus
Armata Pharmaceuticals secures additional DoD funding By Investing.com - Investing.com Nigeria
Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance
New Strong Sell Stocks for April 28th - The Globe and Mail
New Strong Sell Stocks for April 24th - TradingView
Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World
Bacteriophage Therapy Market Future Business Opportunities - openPR
HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World
Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus
Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN
Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz
Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire
Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter
Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia
Armata Pharmaceuticals secures $10 million credit - Investing.com India
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress
2.13%
1.01%
大文字化:
|
ボリューム (24 時間):